#USA #Los Angeles #Schall Law Firm #Securities Fraud #Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Faces Legal Action

Investors of Regeneron Pharmaceuticals, Inc. have recently been reminded of a significant opportunity to participate in a class action lawsuit led by the Schall Law Firm. This legal action comes in light of allegations of securities fraud that occurred during a designated class period spanning from November 2, 2023, to October 30, 2024. The firm is encouraging those who purchased Regeneron's securities during this time to make contact before the deadline of March 10, 2025.

Background of the Case

The Schall Law Firm is a well-known national litigation firm specializing in shareholder rights, and they are urging affected parties to get involved. According to their findings, Regeneron purportedly made misleading statements that not only inflated their stock prices but also contributed to unnecessary damages to shareholders. Central to the accusations is the claim that Regeneron improperly financed credit card transaction fees for distributors, a move that allowed those distributors to sell the drug Eylea at a convolutedly lower price to consumers.

This act, allegedly aimed at increasing Eylea's sales, is said to have led to violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934, alongside Rule 10b-5 enacted by the U.S. Securities and Exchange Commission. The firm has stated that these actions constituted a significant false representation, misleading the market about Regeneron's true financial performance and product viability.

Implications for Investors

Shareholders who faced losses due to these misleading assertions are encouraged to actively participate in the ongoing lawsuit to potentially recover their damages. Anyone interested in exploring their legal options can contact Brian Schall at the Schall Law Firm’s Los Angeles office. The firm is providing this consultation free of charge and emphasizes the importance of swift action as the class has yet to be certified.

Addressing Legal Options

The firm advises that if any investor chooses not to take action, they may end up as an absent class member, effectively losing any opportunity to recover losses they may have incurred. It's crucial for shareholders to understand their rights and the potential course of legal action surrounding Regeneron's conduct.

Schall Law Firm has built a reputation for representing investors globally and specializes in handling complex securities litigation. They reiterate their commitment to advocating for the rights of aggrieved shareholders in class action suits.

Next Steps for Affected Investors

If you are a Regeneron shareholder who purchased within the specified class period, take action now. Reach out to the Schall Law Firm using the information provided on their official website. The potential for recovery could be substantial, depending on the class action outcome.

Shareholders are once again reminded of the deadline for joining this case: March 10, 2025. The pursuit of justice and transparency within the securities market is crucial, and Regeneron investors now have a unique chance to make their voices heard.

For more information, visit Schall Law Firm's website or call 310-301-3335.